Cargando…
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
Diabetic kidney disease (DKD) is one of the most common complications in type 2 diabetes mellitus (T2D) and a major cause of morbidity and mortality in diabetes. Despite the widespread use of nephroprotective treatment of T2D, the incidence of DKD is increasing, and it is expected to become the fift...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432108/ https://www.ncbi.nlm.nih.gov/pubmed/34501404 http://dx.doi.org/10.3390/jcm10173955 |
_version_ | 1783751087503704064 |
---|---|
author | Rojano Toimil, Alba Ciudin, Andreea |
author_facet | Rojano Toimil, Alba Ciudin, Andreea |
author_sort | Rojano Toimil, Alba |
collection | PubMed |
description | Diabetic kidney disease (DKD) is one of the most common complications in type 2 diabetes mellitus (T2D) and a major cause of morbidity and mortality in diabetes. Despite the widespread use of nephroprotective treatment of T2D, the incidence of DKD is increasing, and it is expected to become the fifth cause of death worldwide within 20 years. Previous studies have demonstrated that GLP-1 receptor agonists (GLP-1 RA) have improved macrovascular and microvascular outcomes independent of glycemic differences, including DKD. GLP-1Ras’ improvement on kidney physiology is mediated by natriuresis, reduction in hyperfiltration and renin-angiotensin-aldosterone system (RAAS) activity and anti-inflammatory properties. These findings translate into improved clinical outcomes such as an enhanced urine albumin-to-creatinine ratio (UACR) and a reduction in renal impairment and the need for renal replacement therapies (RRT). In this article, we review the role of GLP-1RAs on the mechanisms and effect in DKD and their clinical efficacy. |
format | Online Article Text |
id | pubmed-8432108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84321082021-09-11 GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes Rojano Toimil, Alba Ciudin, Andreea J Clin Med Review Diabetic kidney disease (DKD) is one of the most common complications in type 2 diabetes mellitus (T2D) and a major cause of morbidity and mortality in diabetes. Despite the widespread use of nephroprotective treatment of T2D, the incidence of DKD is increasing, and it is expected to become the fifth cause of death worldwide within 20 years. Previous studies have demonstrated that GLP-1 receptor agonists (GLP-1 RA) have improved macrovascular and microvascular outcomes independent of glycemic differences, including DKD. GLP-1Ras’ improvement on kidney physiology is mediated by natriuresis, reduction in hyperfiltration and renin-angiotensin-aldosterone system (RAAS) activity and anti-inflammatory properties. These findings translate into improved clinical outcomes such as an enhanced urine albumin-to-creatinine ratio (UACR) and a reduction in renal impairment and the need for renal replacement therapies (RRT). In this article, we review the role of GLP-1RAs on the mechanisms and effect in DKD and their clinical efficacy. MDPI 2021-08-31 /pmc/articles/PMC8432108/ /pubmed/34501404 http://dx.doi.org/10.3390/jcm10173955 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rojano Toimil, Alba Ciudin, Andreea GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes |
title | GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes |
title_full | GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes |
title_fullStr | GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes |
title_full_unstemmed | GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes |
title_short | GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes |
title_sort | glp-1 receptor agonists in diabetic kidney disease: from physiology to clinical outcomes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432108/ https://www.ncbi.nlm.nih.gov/pubmed/34501404 http://dx.doi.org/10.3390/jcm10173955 |
work_keys_str_mv | AT rojanotoimilalba glp1receptoragonistsindiabetickidneydiseasefromphysiologytoclinicaloutcomes AT ciudinandreea glp1receptoragonistsindiabetickidneydiseasefromphysiologytoclinicaloutcomes |